Pfizer Says Vaccine For Kids Ages 5-11 Is 91% Effective

A Pfizer study tracked 2,268 kids in that age group who got two shots three weeks apart of either a placebo or the low-dose vaccine.

Kid-size doses of Pfizer's COVID-19 vaccine appear safe and nearly 91% effective at preventing symptomatic infections in 5- to 11-year-olds, according to study details released Friday as the U.S. considers opening vaccinations to that age group.

The shots could begin in early November — with the first children in line fully protected by Christmas — if regulators give the go-ahead.

Details of Pfizer's study were posted online. The Food and Drug Administration was expected to post its independent review of the company's safety and effectiveness data later in the day.